Biogen (BIIB) Cash & Equivalents (2009 - 2026)

Biogen (BIIB) has reported Cash & Equivalents for 18 consecutive years, with $3.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 30.19% year-over-year to $3.4 billion; the TTM figure through Mar 2026 stood at $3.4 billion (up 30.19% YoY), while the FY2025 annual figure was $3.0 billion, up 26.67% from the prior year.
• Cash & Equivalents came in at $3.4 billion for Q1 2026 at Biogen, up from $3.0 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $3.9 billion in Q3 2025, with the low at $1.0 billion in Q4 2023.
• Average Cash & Equivalents over 5 years is $2.5 billion, with a median of $2.6 billion recorded in 2023.
• Across the five-year window, Cash & Equivalents sank 69.29% in 2023 and soared 141.84% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $3.4 billion in 2022, then tumbled by 69.29% to $1.0 billion in 2023, then jumped by 126.21% to $2.4 billion in 2024, then advanced by 26.67% to $3.0 billion in 2025, then advanced by 12.44% to $3.4 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.4 billion, $3.0 billion, and $3.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.